Pregnancy and Developmental Toxicology – Revised:ED3 10/19/20
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
FDA Guidance on Establishing Pregnancy Exposure Registries
Guidance for Industry Establishing Pregnancy Exposure Registries U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical Guidance for Industry Establishing Pregnancy Exposure Registries Additional copies are available from: Office of Training and Communications Division of Communications Management Drug Information Branch, HFD-210 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm or Office of Communication, Training, and Manufacturers Assistance (HFM-40) Center for Biologics Evaluation and Research (CBER) 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/cber/guidelines.htm (Fax) 888-CBERFAX or 301-827-3844 (Voice Information) 800-835-4709 or 301-827-1800 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2002 Clinical/Medical TABLE OF CONTENTS I. INTRODUCTION................................................................................................................. 1 II. BACKGROUND ...................................................................................................................1 III. WHAT IS A PREGNANCY EXPOSURE REGISTRY? .................................................. 2 IV. WHAT MEDICAL PRODUCTS MAKE GOOD REGISTRY CANDIDATES?........... 3 V. WHEN SHOULD SUCH A REGISTRY BE ESTABLISHED?...................................... -
Safety of Immunization During Pregnancy a Review of the Evidence
Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. -
Conventional Gasoline
Conventional Gasoline M a t e r i a l S a f e t y D a t a S h e e t 1. PRODUCT AND COMPANY IDENTIFICATION Product Name: Conventional Gasoline MSDS Code: 251720 Synonyms: Gasoline, Unleaded, Conventional (All Grades); Gasoline, Low Sulfur Unleaded (All Grades) Intended Use: Fuel Responsible Party: ConocoPhillips 600 N. Dairy Ashford Houston, Texas 77079-1175 Customer Service: 800-640-1956 Technical Information: 800-255-9556 MSDS Information: Phone: 800-762-0942 Email: [email protected] Internet: http://w3.conocophillips.com/NetMSDS/ Emergency Telephone Numbers: Chemtrec: 800-424-9300 (24 Hours) California Poison Control System: 800-356-3219 2. HAZARDS IDENTIFICATION Emergency Overview NFPA DANGER! Extremely Flammable Liquid and Vapor Skin Irritant Aspiration Hazard Appearance: Clear to amber Physical Form: Liquid Odor: Gasoline Potential Health Effects Eye: Contact may cause mild eye irritation including stinging, watering, and redness. Skin: Skin irritant. Contact may cause redness, itching, a burning sensation, and skin damage. Prolonged or repeated contact can defat the skin, causing drying and cracking of the skin, and possibly dermatitis (inflammation). Not acutely toxic by skin absorption, but prolonged or repeated skin contact may be harmful (see Section 11). Inhalation (Breathing): Low to moderate degree of toxicity by inhalation. Ingestion (Swallowing): Low degree of toxicity by ingestion. ASPIRATION HAZARD - This material can enter lungs during swallowing or vomiting and cause lung inflammation and damage. Signs and Symptoms: Effects of overexposure may include nausea, vomiting, flushing, blurred vision, tremors, respiratory failure, signs of nervous system depression (e.g., headache, drowsiness, dizziness, loss of coordination, disorientation and fatigue), unconsciousness, convulsions, death. -
OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters As a Basis for Regulation of Substances with Endocrine Disrupting Properties
OECDOECD ConceptualConceptual FrameworkFramework for forTesting Testing and and Assessment Assessment of Endocrineof EndocrineDisrupters Disruptersas a basis asfor aregulation basis of forsubstances regulation with of substances endocrine disrupting with endocrineproperties disrupting properties Ulla Hass, Majken Dalgaard, Kirsten Jarfelt and Thuri S.A. Kledal Department of Toxicology and Risk Assessment, Danish Institute for Food and Veterinary Research, Denmark TemaNord 2004:555 OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters as a basis for regulation of substances with endocrine disrupting properties TemaNord 2004:555 © Nordic Council of Ministers, Copenhagen 2004 ISBN 92-893-1073-1 ISSN 0908-6692 Nordic Council of Ministers Nordic Council Store Strandstræde 18 Store Strandstræde 18 DK-1255 Copenhagen K DK-1255 Copenhagen K Phone (+45) 3396 0200 Phone (+45) 3396 0400 Fax (+45) 3396 0202 Fax (+45) 3311 1870 www.norden.org Nordic Environmental Co-operation Environmental co-operation is aimed at contributing to the improvement of the environment and forestall problems in the Nordic countries as well as on the international scene. The co- operation is conducted by the Nordic Committee of Senior Officials for Environmental Affairs. The co-operation endeavours to advance joint aims for Action Plans and joint projects, exchange of information and assistance, e.g. to Eastern Europe, through the Nordic Environmental Finance Corporation (NEFCO). The Nordic Council of Ministers was established in 1971. It submits proposals on co-operation between the governments of the five Nordic countries to the Nordic Council, implements the Council's recommendations and reports on results, while directing the work carried out in the targeted areas. The Prime Ministers of the five Nordic countries assume overall responsibility for the co-operation measures, which are co-ordinated by the ministers for co-operation and the Nordic Co-operation committee. -
Fighting Bisphenol A-Induced Male Infertility: the Power of Antioxidants
antioxidants Review Fighting Bisphenol A-Induced Male Infertility: The Power of Antioxidants Joana Santiago 1 , Joana V. Silva 1,2,3 , Manuel A. S. Santos 1 and Margarida Fardilha 1,* 1 Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] (J.S.); [email protected] (J.V.S.); [email protected] (M.A.S.S.) 2 Institute for Innovation and Health Research (I3S), University of Porto, 4200-135 Porto, Portugal 3 Unit for Multidisciplinary Research in Biomedicine, Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal * Correspondence: [email protected]; Tel.: +351-234-247-240 Abstract: Bisphenol A (BPA), a well-known endocrine disruptor present in epoxy resins and poly- carbonate plastics, negatively disturbs the male reproductive system affecting male fertility. In vivo studies showed that BPA exposure has deleterious effects on spermatogenesis by disturbing the hypothalamic–pituitary–gonadal axis and inducing oxidative stress in testis. This compound seems to disrupt hormone signalling even at low concentrations, modifying the levels of inhibin B, oestra- diol, and testosterone. The adverse effects on seminal parameters are mainly supported by studies based on urinary BPA concentration, showing a negative association between BPA levels and sperm concentration, motility, and sperm DNA damage. Recent studies explored potential approaches to treat or prevent BPA-induced testicular toxicity and male infertility. Since the effect of BPA on testicular cells and spermatozoa is associated with an increased production of reactive oxygen species, most of the pharmacological approaches are based on the use of natural or synthetic antioxidants. -
Toxicological Profile for Bisphenol A
TT TOXICOLOGICAL PROFILE FOR BISPHENOL A September 2009 Integrated Risk Assessment Branch Office of Environmental Health Hazard Assessment California Environmental Protection Agency Toxicological Profile for Bisphenol A September 2009 Prepared by Office of Environmental Health Hazard Assessment Prepared for Ocean Protection Council Under an Interagency Agreement, Number 07-055, with the State Coastal Conservancy LIST OF CONTRIBUTORS Authors Jim Carlisle, D.V.M., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch Dave Chan, D. Env., Staff Toxicologist, Integrated Risk Assessment Branch Mari Golub, Ph.D., Staff Toxicologist, Reproductive and Cancer Hazard Assessment Branch Sarah Henkel, Ph.D., California Sea Grant Fellow, California Ocean Science Trust Page Painter, M.D., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch K. Lily Wu, Ph.D., Associate Toxicologist, Reproductive and Cancer Hazard Assessment Branch Reviewers David Siegel, Ph.D., Chief, Integrated Risk Assessment Branch i Table of Contents Executive Summary ................................................................................................................................ iv Use and Exposure ............................................................................................................................... iv Environmental Occurrence ................................................................................................................. iv Effects on Aquatic Life ...................................................................................................................... -
Committee for Risk Assessment RAC Opinion Proposing Harmonised
Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of 2-Ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex EC Number: - CAS Number: - CLH-O-0000006817-63-01/F Adopted 11 June 2020 P.O. Box 400, FI-00121 Helsinki, Finland | Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu [04.01-ML-014.03] 11 June 2020 CLH-O-0000006817-63-01/F OPINION OF THE COMMITTEE FOR RISK ASSESSMENT ON A DOSSIER PROPOSING HARMONISED CLASSIFICATION AND LABELLING AT EU LEVEL In accordance with Article 37 (4) of Regulation (EC) No 1272/2008, the Classification, Labelling and Packaging (CLP) Regulation, the Committee for Risk Assessment (RAC) has adopted an opinion on the proposal for harmonised classification and labelling (CLH) of: Chemical name: 2-Ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex EC Number: - CAS Number: - The proposal was submitted by Spain and received by RAC on 16 April 2019. In this opinion, all classification and labelling elements are given in accordance with the CLP Regulation. PROCESS FOR ADOPTION OF THE OPINION Spain has submitted a CLH dossier containing a proposal together with the justification and background information documented in a CLH report. The CLH report was made publicly available in accordance with the requirements of the CLP Regulation at http://echa.europa.eu/harmonised-classification-and-labelling-consultation/ on 27 May 2019. Concerned parties and Member State Competent Authorities (MSCA) were invited to submit comments and contributions by 26 July 2019. -
Toxicological and Health Aspects of Bisphenol A
Toxicological and Health Aspects of Bisphenol A Report of Joint FAO/WHO Expert Meeting 2–5 November 2010 and Report of Stakeholder Meeting on Bisphenol A 1 November 2010 Ottawa, Canada Food and Agriculture Organization of the United Nations WHO Library Cataloguing-in-Publication Data Joint FAO/WHO expert meeting to review toxicological and health aspects of bisphenol A: final report, including report of stakeholder meeting on bisphenol A, 1-5 November 2010, Ottawa, Canada. 1.Phenols - toxicity. 2.Food contamination. 3.Food packing. I.World Health Organization. II.Food and Agriculture Organization of the United Nations. ISBN 978 92 14 156427 4 (NLM classification: QV 223) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. -
Guidelines for Developmental Toxicity Risk Assessment
EPA/600/FR-91/001 December 1991 Guidelines for Developmental Toxicity Risk Assessment Published on December 5, 1991, Federal Register 56(234):63798-63826 Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document represents the final guidelines. A number of editorial corrections have been made during conversion and subsequent proofreading to ensure the accuracy of this publication. ii CONTENTS Lists of Tables and Figures ........................................................v Federal Register Preamble ....................................................... vi Part A: Guidelines for Developmental Toxicity Risk Assessment 1. Introduction ................................................................1 2. Definitions and Terminology ....................................................3 3. Hazard Identification/Dose-Response Evaluation of Agents That Cause Developmental Toxicit y 4 3.1. Developmental Toxicity Studies: Endpoints and Their Interpretation ..................5 3.1.1. Laboratory Animal Studies ..........................................5 3.1.1.1 Endpoints of Maternal Toxicity . 7 3.1.1.2. Endpoints of Developmental Toxicity: Altered Survival, Growth, and Morphological Development ........................9 3.1.1.3. Endpoints of Developmental Toxicity: Functional -
STATE of the ART ASSESSMENT of ENDOCRINE DISRUPTERS Final Report
STATE OF THE ART ASSESSMENT OF ENDOCRINE DISRUPTERS Final Report Project Contract Number 070307/2009/550687/SER/D3 Authors: Andreas Kortenkamp, Olwenn Martin, Michael Faust, Richard Evans, Rebecca McKinlay, Frances Orton and Erika Rosivatz 23.12.2011 TABLE OF CONTENTS TABLE OF CONTENTS 0 EXECUTIVE SUMMARY ......................................................................................................................... 7 1 INTRODUCTION .................................................................................................................................... 9 1.1 TERMS OF REFERENCE, SCOPE OF THE REPORT ........................................................................... 9 1.2 STRUCTURE OF THE REPORT ....................................................................................................... 11 2 DEFINITION OF ENDOCRINE DISRUPTING CHEMICALS ...................................................................... 13 2.1 THE ENDOCRINE SYSTEM ............................................................................................................ 13 2.2 ADVERSITY ................................................................................................................................... 15 2.2.1 DEFINITION........................................................................................................................... 15 2.2.2 ASSAY REQUIREMENTS ........................................................................................................ 16 2.2.3 ECOTOXICOLOGICAL EFFECTS ............................................................................................. -
Benzyl Butyl Phthalate Or BBP)
Toxicity Review for Benzylnbutyl Phthalate (Benzyl Butyl Phthalate or BBP) Introduction Benzyl butyl phthalate (BBP) is a man‐made phthalate ester that is mostly used in vinyl tile (CERHR, 2003). BBP can also be found as a plasticizer in polyvinyl chloride (PVC) for the manufacturing of conveyor belts, carpet, weather stripping and more. It is also found in some vinyl gloves and adhesives. BBP is produced by the sequential reaction of butanol and benzyl chloride with phthalic anhydride (CERHR, 2003). The Monsanto Company is the only US producer of BBP (IPCS, 1999). When BBP is added during the manufacturing of a product, it is not bound to the final product. However, through the use and disposal of the product, BBP can be released into the environment. BBP can be deposited on and taken up by crops for human and livestock consumption, resulting in its entry into the food chain (CERHR, 2003). Concentrations of BBP have been found in ambient and indoor air, drinking water, and soil. However, the concentrations are low and intakes from these routes are considered negligible (IPCS, 1999). Exposure to BBP in the general population is based on food intake. Occupational exposure to BBP is possible through skin contact and inhalation, but data on BBP concentrations in the occupational environment is limited. Unlike some other phthalates, BBP is not approved by the U.S. Food and Drug Administration for use in medicine or medical devices (IPCS, 1999; CERHR, 2003). Based on the National Toxicology Program (NTP) bioassay reports of increased pancreatic lesions in male rats, a tolerable daily intake of 1300 µg/kg body weight per day (µg/kg‐d) has been calculated for BBP by the International Programme on Chemical Safety (IPCS) (IPCS, 1999). -
Toxicological Summary for Bisphenol a (PDF)
Health Based Guidance for Water Health Risk Assessment Unit, Environmental Health Division 651-201-4899 Adopted as Rule: November 2015 Toxicological Summary for: Bisphenol A CAS: 80-05-7 Synonyms: BPA; 4'-(1-Methylethylidene)bisphenol 4,4'-Bisphenol A; 4,4'- Isopropylidenediphenol; Phenol, 4,4'-(1-methylethylidene)bis- p,p'- isopropylidenebisphenol; 2,2-bis(4-hydroxyphenyl)propane Acute Non-Cancer Health Risk Limit (nHRLAcute) = Not Derived (Insufficient Data) Short-term Non-Cancer Health Risk Limit (nHRLShort-term) = 100 µg/L (Reference Dose, mg/kg/d) x (Relative Source Contribution) x (Conversion Factor) (Short-term intake rate, L/kg-d) = (0.16 mg/kg/d) x (0.2*) x (1000 µg/mg) (0.289 L/kg-d) = 111 rounded to 100 µg/L *MDH utilizes the EPA Exposure Decision Tree (EPA 2000) to select appropriate RSCs. Given the significant potential non- drinking water sources of exposure from multiple sources available for infants, an RSC of 0.2 is selected rather than the default value of 0.5 used for nonvolatile chemicals. Reference Dose/Concentration 0.16 mg/kg-d (rat) Source of toxicity value MDH, 2014 Point of Departure (POD): 2.7 mg/kg-d (NOAEL, Delclos et al. 2014) Human Equivalent Dose (MDH, 2011: 2.7 x 5.8 = 16 mg/kg-d [chemical-specific DAF for neonatal rats] Total uncertainty factor: 100 Uncertainty factor allocation 3 for interspecies differences (for toxicodynamics), 10 for intraspecies variability, and 3 for database uncertainty (additional studies to evaluate latent effects of early life exposure, neurobehavioral, immune system, and metabolic